GlassScriptPhysician profile
Mark O Carlson
NPI 1609837368
$173,867.87
in general payments reported to CMS, 2019-2025
44 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $8,083 · 2021: $68K · 2022: $29K · 2023: $47K · 2024: $5,659 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $6,654 · Food and Beverage: $3,073 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,204.75 |
| Travel and Lodging | $6,653.70 |
| Food and Beverage | $3,073.00 |
| Education | $100.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $165,541.52 | 2019-2025 | Repatha, Otezla, Prolia |
| Allergan, INC. | $1,489.44 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,095.23 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $536.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $499.46 | 2021-2025 | |
| Esperion Therapeutics, INC. | $499.21 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $424.37 | 2020-2022 | |
| Pfizer INC. | $385.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $311.49 | 2019-2024 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.66 | 2019-2022 | |
| Radius Health, INC. | $296.70 | 2019-2025 | Tymlos |
| Astellas Pharma US INC | $255.15 | 2023-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $230.09 | 2019-2023 | Xarelto |
| Pacira Therapeutics, INC. | $204.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $181.80 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.